AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC after both sandblasting with 50μm aluminium oxide and deproteinization with 5.25% NaOCl, followed by etching with 37% phosphoric acid
Number of subjects: 150
Study 25963642 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcultural prevention approach (prevention event + cultural and language-sensitive information booklet)
Number of subjects: 310
Study 25963642 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcultural prevention approach
Number of subjects: 310
Study 25963642 — intervention group
Group type: COMPARATOR
Intervention: Control condition (general prevention event with materials from Deutsche Hauptstelle für Suchtfragen)
Number of subjects: 310
Study 23864054 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine-ARB
Number of subjects: 834
Study 23864054 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine-BB
Number of subjects: 834
Study 23864054 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine-TD
Number of subjects: 834
Study 23864054 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 834
Study 21677895 — intervention group
Group type: EXPERIMENTAL
Intervention: SensAwake ON
Number of subjects: 42
Study 21677895 — intervention group
Group type: COMPARATOR
Intervention: SensAwake OFF
Number of subjects: 42
Study 21677895 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoCPAP AHI
Number of subjects: 42
Study 19672264 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) 1000 mg m(‐2) on D1, 8, 15 q28d (Arm A)
Number of subjects: 86
Study 19672264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (C) 25 mg m(‐2) followed by Gemcitabine (G) 1000 mg m(‐2) D1, 8 q21d (Arm B)
Number of subjects: 86
Study 16413247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (8 oz)
Number of subjects: 14
Study 16413247 — intervention group
Group type: COMPARATOR
Intervention: Cranberry juice placebo (8 oz)
Number of subjects: 14
Study 16413247 — intervention group
Group type: EXPERIMENTAL
Intervention: Brewed tea (8 oz)
Number of subjects: 14
Study 16413247 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice (8 oz)
Number of subjects: 14
Study 16413247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (8 oz)
Number of subjects: 14
Study 15322323 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 20
Study 15322323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15322323 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil vs. Placebo
Number of subjects: 20
Study 15322323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 20
Study 11372549 — intervention group
Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl 0.15%
Number of subjects: 12
Study 11372549 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 9240593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow dose of parenteral estradiol (7.5 microg/24 hours) delivered by vaginal rings
Number of subjects: 30
Study 9240593 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study 8204230 — intervention group
Group type: EXPERIMENTAL
Intervention: GA/PM (general anesthesia-parenteral morphine as needed)
Number of subjects: 36
Study 8204230 — intervention group
Group type: EXPERIMENTAL
Intervention: EA/PM (epidural anesthesia-parenteral morphine as needed)
Number of subjects: 36
Study 8204230 — intervention group
Group type: EXPERIMENTAL
Intervention: EA/EM (epidural anesthesia-epidural morphine 4 to 5 mg)
Number of subjects: 36
Study 8204230 — intervention group
Group type: EXPERIMENTAL
Intervention: EA/EM
Number of subjects: 36
Study 3499730 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 3499730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31749018 — intervention group
Group type: COMPARATOR
Intervention: Active Control Intervention (ACI), educational lessons
Number of subjects: 128
Study 31749018 — intervention group
Group type: COMPARATOR
Intervention: Partial Intervention (PI), homotaurine administration (100 mg/die) and lessons on the Mediterranean diet
Number of subjects: 128
Study 31749018 — intervention group
Group type: COMPARATOR
Intervention: Multilevel Intervention (MI), PI plus computerized cognitive training and physical exercise training
Number of subjects: 128
Study 28495209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule initiated by one child
Number of subjects: 3
Study 28495209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule initiated collaboratively
Number of subjects: 3
Study 28495209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule initiated by an adult authority figure
Number of subjects: 3
Study 28495209 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's own solitary rule
Number of subjects: 3
Study 28495209 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral and conventional rules in daily life
Number of subjects: 3
Study 26660396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fones technique training
Number of subjects: 70
Study 26660396 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bass technique training
Number of subjects: 70
Study 26660396 — intervention group
Group type: COMPARATOR
Intervention: Basic instructions of oral hygiene (control group)
Number of subjects: 70
Study 26660396 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 70
Study 24393153 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical regular crystalline insulin (containing zinc)
Number of subjects: 90
Study 24393153 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous zinc chloride solution
Number of subjects: 90
Study 24393153 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 90
Study 24393153 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute wounds
Number of subjects: 90
Study 24393153 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients ≤40 years
Number of subjects: 90
Study 24393153 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body wounds
Number of subjects: 90
Study 22836067 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin therapy
Number of subjects: 0
Study 22836067 — intervention group
Group type: COMPARATOR
Intervention: AIM-HIGH trial
Number of subjects: 0
Study 19561649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beclomethasone dipropionate (BDP)
Number of subjects: 120
Study 19561649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18174038 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate, high-fat (VLCHF) diet
Number of subjects: 88
Study 18174038 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat (HCLF) diet
Number of subjects: 88
Study 14982679 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation Anxiety Test (SAT)
Number of subjects: 60
Study 14982679 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to pictures of children about to experience pain in the presence of parent figures
Number of subjects: 60
Study 11275884 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 24 months (Group A)
Number of subjects: 42
Study 11275884 — intervention group
Group type: COMPARATOR
Intervention: Follow-up at 48 months (Group B)
Number of subjects: 42
Study 9397127 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-point nursing intervention for parents
Number of subjects: 50
Study 9397127 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 50
Study 8200210 — intervention group
Group type: EXPERIMENTAL
Intervention: One Touch II blood glucose meter
Number of subjects: 267
Study 3610513 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine
Number of subjects: 0
Study 3610513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31803482 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP1RA+BI (detemir plus liraglutide)
Number of subjects: 120
Study 31803482 — intervention group
Group type: COMPARATOR
Intervention: BBI (detemir plus aspart)
Number of subjects: 120
Study 31803482 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP1RA+BI
Number of subjects: 120
Study 31803482 — intervention group
Group type: COMPARATOR
Intervention: BBI
Number of subjects: 120
Study 29401239 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy of underlying conditions (including mineralocorticoid receptor antagonists, statins, ACE inhibitors/ARBs, and cardiac rehabilitation)
Number of subjects: 245
Study 29401239 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 245
Study 26670823 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (CBT) for insomnia, delivered in a five-session format.
Number of subjects: 239
Study 26670823 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) for insomnia delivered by mental health practitioners.
Number of subjects: 239
Study 26670823 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT for insomnia at 20 weeks follow-up.
Number of subjects: 239
Study 26670823 — intervention group
Group type: COMPARATOR
Intervention: TAU for insomnia at 20 weeks follow-up.
Number of subjects: 239
Study 24447519 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-led care (prednisone, tacrolimus, mycophenolate mofetil)
Number of subjects: 0
Study 24447519 — intervention group
Group type: COMPARATOR
Intervention: Standard care (current therapy)
Number of subjects: 0
Study 24447519 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-led care
Number of subjects: 0
Study 24447519 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 23049836 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly installment schedule
Number of subjects: 200
Study 20943938 — intervention group
Group type: EXPERIMENTAL
Intervention: Disasters spreading from a different state (earthquake, environmental risk)
Number of subjects: 3
Study 20943938 — intervention group
Group type: COMPARATOR
Intervention: Disasters spreading from the same state
Number of subjects: 3
Study 17539894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 48
Study 17539894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d. with naltrexone 50 mg
Number of subjects: 48
Study 17539894 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 50 mg
Number of subjects: 48
Study 17539894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d. and Tegaserod with naltrexone 50 mg
Number of subjects: 48
Study 15882796 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced trials
Number of subjects: 0
Study 15882796 — intervention group
Group type: COMPARATOR
Intervention: Simple reaction time instruction
Number of subjects: 0
Study 11426365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital Capacity Maneuver (VCM)
Number of subjects: 40
Study 11426365 — intervention group
Group type: COMPARATOR
Intervention: Control (no VCM)
Number of subjects: 40
Study 9412612 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (12 g as an initial intravenous bolus, 12 g daily for 4 weeks, and 4.8 g daily for 8 weeks)
Number of subjects: 927
Study 9412612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 9412612 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (in early treatment subgroup)
Number of subjects: 927
Study 9412612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in early treatment subgroup)
Number of subjects: 927
Study 9412612 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (in subgroup of patients with moderate and severe stroke)
Number of subjects: 927
Study 8213795 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa solution
Number of subjects: 36
Study 8213795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle (including citrate component)
Number of subjects: 36
Study 8213795 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate component of the vehicle
Number of subjects: 36
Study 8213795 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin component of the vehicle
Number of subjects: 36
Study 8213795 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study 3688536 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide
Number of subjects: 18
Study 3688536 — intervention group
Group type: COMPARATOR
Intervention: 60% nitrogen (control)
Number of subjects: 18
Study 30967131 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (HBEI) for 12 weeks, including four 2-hour sessions supervised by a physiotherapist and fortnightly telephone support, combined with health education.
Number of subjects: 171
Study 30967131 — intervention group
Group type: COMPARATOR
Intervention: Health education only (Control group).
Number of subjects: 171
Study 30967131 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (HBEI) for 12 weeks.
Number of subjects: 171
Study 29109237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 0
Study 29109237 — intervention group
Group type: COMPARATOR
Intervention: Sleep Control
Number of subjects: 0
Study 25439595 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 759
Study 25439595 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 759
Study 25439595 — intervention group
Group type: COMPARATOR
Intervention: sham/0.5 mg crossover
Number of subjects: 759
Study 25439595 — intervention group
Group type: COMPARATOR
Intervention: sham/0.5 mg
Number of subjects: 759
Study 24132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at diagnosis
Number of subjects: 127
Study 24132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger left ventricular (LV) end-diastolic M-mode dimension z-score
Number of subjects: 127
Study 24132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower septal peak systolic tissue Doppler velocity z-score
Number of subjects: 127
Study 24132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification and regression tree analysis
Number of subjects: 127
Study 21705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nike Sensory Station assessments
Number of subjects: 161
Study 19156027 — intervention group
Group type: EXPERIMENTAL
Intervention: Perftoran
Number of subjects: 50
Study 19156027 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 50
Study 16537288 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician characteristics (community vs academic affiliation, enthusiastic vs neutral presentation, new vs previous relationship)
Number of subjects: 262
Study 12743672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 20 mg twice daily, administered either before breakfast and with dinner, or with breakfast and after dinner.
Number of subjects: 0
Study 12743672 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of ximelagatran (1-98 mg) in a dose-escalation study.
Number of subjects: 0
Study 11074230 — intervention group
Group type: EXPERIMENTAL
Intervention: Late partial sleep deprivation (sleep 9:00 PM‐1:00 AM)
Number of subjects: 30
Study 11074230 — intervention group
Group type: EXPERIMENTAL
Intervention: Early partial sleep deprivation (sleep 3:00 AM‐7:00 AM)
Number of subjects: 30
Study 11074230 — intervention group
Group type: COMPARATOR
Intervention: Midfollicular (MF) phase
Number of subjects: 30
Study 11074230 — intervention group
Group type: COMPARATOR
Intervention: Late luteal (LL) phase
Number of subjects: 30
Study 9058867 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed polarity (distal electrode = anode)
Number of subjects: 27
Study 9058867 — intervention group
Group type: COMPARATOR
Intervention: Initial polarity (distal electrode = cathode)
Number of subjects: 27
Study 8362451 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0
Study 8362451 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole (400 mg)
Number of subjects: 0
Study 30357555 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC plus systematic EPC
Number of subjects: 186
Study 30357555 — intervention group
Group type: COMPARATOR
Intervention: SCC plus on-demand EPC
Number of subjects: 186
Study 30070733 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CSPS dentifrice
Number of subjects: 0
Study 30070733 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CSPS slurry
Number of subjects: 0
Study 30070733 — intervention group
Group type: COMPARATOR
Intervention: 0% CSPS dentifrice
Number of subjects: 0
Study 30070733 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CSPS dentifrice and 0% CSPS dentifrice
Number of subjects: 0
Study 30070733 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 27614872 — intervention group
Group type: EXPERIMENTAL
Intervention: GC + N (Gemcitabine, Cisplatin + Necitumumab)
Number of subjects: 96
Study 27614872 — intervention group
Group type: COMPARATOR
Intervention: GC (Gemcitabine, Cisplatin)
Number of subjects: 96
Study 24495781 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐month extended contact intervention (Get Healthy, Stay Healthy, GHSH)
Number of subjects: 0
Study 24495781 — intervention group
Group type: COMPARATOR
Intervention: No contact control group (standard practice following GHS completion)
Number of subjects: 0
Study 22214924 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated salivary cortisol
Number of subjects: 262
Study 22214924 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol at 2300 h
Number of subjects: 262
Study 22214924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-suppressed salivary cortisol at 0800 h
Number of subjects: 262
Study 20462038 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangliu Zengxiao Decoction (KLZX) in addition to chemotherapy NP regimen
Number of subjects: 61
Study 20462038 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy NP regimen alone
Number of subjects: 61
Study 18678792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion hydrochloride started at 150 mg/d and increased to 400 mg/d
Number of subjects: 727
Study 18678792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride started at 50 mg/d and increased to 200 mg/d
Number of subjects: 727
Study 18678792 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine hydrochloride started at 37.5 mg/d and increased to 375 mg/d
Number of subjects: 727
Study 15900007 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2) plus docetaxel (75 mg/m2)
Number of subjects: 627
Study 15900007 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2)
Number of subjects: 627
Study 12727169 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified small bowel follow-through (SBFT)
Number of subjects: 62
Study 12727169 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Control group)
Number of subjects: 62
Study 10321329 — intervention group
Group type: EXPERIMENTAL
Intervention: R3 component of the blink reflex in MS patients
Number of subjects: 20
Study 10321329 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 20
Study 8712652 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine sulphate (MST) and 10 mg metoclopramide every 8 h for 48 h
Number of subjects: 0
Study 8712652 — intervention group
Group type: COMPARATOR
Intervention: 75 mg diclofenac twice daily for 48 h
Number of subjects: 0
Study 8712652 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine sulphate (MST)
Number of subjects: 0
Study 1655107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg day‐1) for 4 weeks
Number of subjects: 23
Study 1655107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg day‐1) for 52 weeks
Number of subjects: 23
Study 1655107 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 23
Study 1655107 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label Sorbinil for 52 weeks
Number of subjects: 23
Study 7035745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including platinum
Number of subjects: 250
Study 7035745 — intervention group
Group type: COMPARATOR
Intervention: Single agent chemotherapy
Number of subjects: 250
Study 29989335 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla300)
Number of subjects: 24
Study 29989335 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec U100 (Deg)
Number of subjects: 24
Study 27935229 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 64
Study 27935229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27805473 — intervention group
Group type: EXPERIMENTAL
Intervention: Link with no disclosure
Number of subjects: 1071
Study 27805473 — intervention group
Group type: EXPERIMENTAL
Intervention: Link with a simple nonsponsorship disclosure
Number of subjects: 1071
Study 27805473 — intervention group
Group type: EXPERIMENTAL
Intervention: Link with a detailed nonsponsorship disclosure
Number of subjects: 1071
Study 27805473 — intervention group
Group type: COMPARATOR
Intervention: Control (no link to a disease information website)
Number of subjects: 1071
Study 25030181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 µg + insulin
Number of subjects: 10
Study 25030181 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (control)
Number of subjects: 10
Study 25030181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 µg + insulin
Number of subjects: 10
Study 21257052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentrate diet plus enzyme (LCE)
Number of subjects: 60
Study 21257052 — intervention group
Group type: COMPARATOR
Intervention: High-concentrate diet (HC)
Number of subjects: 60
Study 21257052 — intervention group
Group type: COMPARATOR
Intervention: Low-concentrate diet (LC)
Number of subjects: 60
Study 21257052 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentrate diet plus enzyme (HCE)
Number of subjects: 60
Study 19497153 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 39
Study 19497153 — intervention group
Group type: COMPARATOR
Intervention: OC1/20
Number of subjects: 39